Tempest Total Assets from 2010 to 2024

TPST Stock

USD 0.94 0.02 2.17%

Tempest Therapeutics Total Assets yearly trend continues to be comparatively stable with very little volatility. Total Assets are likely to outpace its year average in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2012-06-30

Previous Quarter

42.2 M

Current Value

33.8 M

Quarterly Volatility

38.6 M

Yuan Drop

Covid

Check Tempest Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tempest Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 361.9 K, Interest Expense of 1.5 M or Selling General Administrative of 15.4 M, as well as many indicators such as Price To Sales Ratio of 1.36, Dividend Yield of 0.0 or PTB Ratio of 3.14. Tempest financial statements analysis is a perfect complement when working with Tempest Therapeutics Valuation or Volatility modules.

Check out the analysis of Tempest Therapeutics Correlation against competitors.

For more information on how to buy Tempest Stock please use our How to Invest in Tempest Therapeutics guide.

Latest Tempest Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Tempest Therapeutics over the last few years. Total assets refers to the total amount of Tempest Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Tempest Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Tempest Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tempest Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 51.6 M

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Total Assets

Timeline

Tempest Total Assets Regression Statistics

	Arithmetic Mean	60,853,381
	Geometric Mean	44,158,094
	Coefficient Of Variation	62.19
	Mean Deviation	28,785,288
	Median	65,572,000
	Standard Deviation	37,846,204
	Sample Variance	1432.3T
	Range	134M
	R-Value	0.26
	Mean Square Error	1436.5T
	R-Squared	0.07
	Significance	0.35
	Slope	2,218,764
	Total Sum of Squares	20052.7T

Tempest Total Assets History

	2024	70.9 M
	2023	51.6 M
	2022	46.1 M
	2021	73.2 M
	2020	22.9 M
	2019	75 M
	2018	84.1 M

Other Fundumenentals of Tempest Therapeutics

Intangibles To Total Assets

Tempest Therapeutics Total Assets component correlations

	Total Assets	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Total Stockholder Equity	Accounts Payable	Short Term Investments	Common Stock	Current Deferred Revenue	Net Receivables	Short Term Debt	Net Tangible Assets	Property Plant Equipment	Net Invested Capital	Capital Stock	Net Working Capital	Long Term Debt	Short Long Term Debt
Total Assets		-0.67	-0.73	-0.17	1.0	0.78	0.8	0.63	0.56	-0.04	0.13	0.01	0.03	0.11	0.01	-0.05	0.06	0.06	-0.04
Net Debt	-0.67		0.5	0.06	-0.69	-0.49	-0.39	-0.06	-0.09	-0.11	-0.13	0.07	0.14	0.05	0.14	0.18	0.03	-0.21	-0.11
Retained Earnings	-0.73	0.5		0.04	-0.7	-0.49	-0.52	-0.35	-0.67	0.19	0.11	-0.22	-0.14	-0.18	-0.11	-0.16	-0.05	0.19	0.19
Total Liab	-0.17	0.06	0.04		-0.19	-0.71	-0.27	-0.34	-0.25	-0.06	0.04	0.22	0.12	-0.34	0.24	0.17	0.26	-0.11	-0.06
Total Current Assets	1.0	-0.69	-0.7	-0.19		0.8	0.81	0.64	0.56	-0.01	0.15	-0.05	-0.04	0.05	-0.06	-0.13	0.03	0.13	-0.01
Total Stockholder Equity	0.78	-0.49	-0.49	-0.71	0.8		0.73	0.7	0.55	0.09	0.1	-0.21	-0.12	0.23	-0.2	-0.2	-0.15	0.18	0.09
Accounts Payable	0.8	-0.39	-0.52	-0.27	0.81	0.73		0.84	0.66	0.19	-0.1	-0.38	-0.37	-0.21	-0.41	-0.39	-0.36	0.32	0.19
Short Term Investments	0.63	-0.06	-0.35	-0.34	0.64	0.7	0.84		0.81	0.28	-0.06	-0.48	-0.42	-0.19	-0.46	-0.4	-0.4	0.36	0.28
Common Stock	0.56	-0.09	-0.67	-0.25	0.56	0.55	0.66	0.81		0.04	-0.3	-0.22	-0.33	-0.06	-0.37	-0.16	-0.41	0.09	0.04
Current Deferred Revenue	-0.04	-0.11	0.19	-0.06	-0.01	0.09	0.19	0.28	0.04		0.23	-0.85	-0.64	-0.43	-0.61	-0.66	-0.45	0.8	1.0
Net Receivables	0.13	-0.13	0.11	0.04	0.15	0.1	-0.1	-0.06	-0.3	0.23		-0.01	0.26	0.18	0.34	-0.04	0.67	0.3	0.23
Short Term Debt	0.01	0.07	-0.22	0.22	-0.05	-0.21	-0.38	-0.48	-0.22	-0.85	-0.01		0.89	0.68	0.87	0.9	0.71	-0.91	-0.85
Net Tangible Assets	0.03	0.14	-0.14	0.12	-0.04	-0.12	-0.37	-0.42	-0.33	-0.64	0.26	0.89		0.79	0.99	0.88	0.86	-0.81	-0.64
Property Plant Equipment	0.11	0.05	-0.18	-0.34	0.05	0.23	-0.21	-0.19	-0.06	-0.43	0.18	0.68	0.79		0.73	0.83	0.6	-0.72	-0.43
Net Invested Capital	0.01	0.14	-0.11	0.24	-0.06	-0.2	-0.41	-0.46	-0.37	-0.61	0.34	0.87	0.99	0.73		0.86	0.91	-0.76	-0.61
Capital Stock	-0.05	0.18	-0.16	0.17	-0.13	-0.2	-0.39	-0.4	-0.16	-0.66	-0.04	0.9	0.88	0.83	0.86		0.65	-0.95	-0.66
Net Working Capital	0.06	0.03	-0.05	0.26	0.03	-0.15	-0.36	-0.4	-0.41	-0.45	0.67	0.71	0.86	0.6	0.91	0.65		-0.48	-0.45
Long Term Debt	0.06	-0.21	0.19	-0.11	0.13	0.18	0.32	0.36	0.09	0.8	0.3	-0.91	-0.81	-0.72	-0.76	-0.95	-0.48		0.8
Short Long Term Debt	-0.04	-0.11	0.19	-0.06	-0.01	0.09	0.19	0.28	0.04	1.0	0.23	-0.85	-0.64	-0.43	-0.61	-0.66	-0.45	0.8

Click cells to compare fundamentals

About Tempest Therapeutics Financial Statements

Tempest Therapeutics shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although Tempest Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Tempest Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Tempest Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

		Last Reported	Projected for Next Year
	Total Assets	51.6 M	70.9 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Tempest Stock Analysis

When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC